You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
In Nature this week: Readfish tool for targeted nanopore sequencing, genomic diversity of barley and wheat, and more.
At the AMP 2020 annual meeting, the Chicago pediatric hospital described how to modernize variant calling, as new human genome assemblies are in the works.
In PLOS this week: method that combines genetic and lab test results from EHRs, leptospirosis microtranscriptome profiles, and more.
CRIOs and their equivalents often are asked to bridge academic and provider sides of institutions to support clinical trials and data analytics with massive research datasets.
In Nature this week: researchers in Canada sequence the genome of the black mustard plant Brassica nigra, and more.
An analysis of whole-exome sequencing, brain gene expression, and health data suggests an autism subtype marked by dyslipidemia.
The Washington Post reports on researchers' efforts to determine the effect of an increasingly common SARS-CoV-2 mutation.
Researchers identified secondary or incidental findings in just over 3 percent of the nearly 22,000 EMERGE III participants, who were profiled with a 109-gene panel.
In PLOS this week: genomic analysis of multidrug-resistant Mycobacterium tuberculosis strains from Colombia, inflammatory response signatures in cancer, and more.
In PNAS this week: comparative genomic analysis to find Pseudomonas aeruginosa virulence genes, "anti-CRISPR" proteins in Staphylococcus aureus, and more.
Imperial College London researchers are shifting away from testing a COVID-19 vaccine to focus on combating newly emerging SARS-CoV-2 variants, the Independent says.
According to the Associated Press, genetic genealogy has helped law enforcement officials identify an unknown victim of the Green River Killer.
In PNAS this week: target to reduce chemotherapy-induced cardiac injury, tool finds ancient endogenous RNA viruses, and more.
Moderna reports its vaccine is effective against new SARS-CoV-2 strains, though it is also developing a booster, according to the New York Times.